SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Kobayashi, M; Vekemans, J; Baker, CJ; Ratner, AJ; Le Doare, K; Schrag, SJ (2016) Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries. F1000Res, 5. p. 2355. ISSN 2046-1402 https://doi.org/10.12688/f1000research.9363.1
SGUL Authors: Le Doare, Kirsty

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

Globally, group B Streptococcus (GBS) remains the leading cause of sepsis and meningitis in young infants, with its greatest burden in the first 90 days of life. Intrapartum antibiotic prophylaxis (IAP) for women at risk of transmitting GBS to their newborns has been effective in reducing, but not eliminating, the young infant GBS disease burden in many high income countries. However, identification of women at risk and administration of IAP is very difficult in many low and middle income country (LMIC) settings, and is not possible for home deliveries. Immunization of pregnant women with a GBS vaccine represents an alternate pathway to protecting newborns from GBS disease, through the transplacental antibody transfer to the fetus in utero. This approach to prevent GBS disease in young infants is currently under development, and is approaching late stage clinical evaluation. This manuscript includes a review of the natural history of the disease, global disease burden estimates, diagnosis and existing control options in different settings, the biological rationale for a vaccine including previous supportive studies, analysis of current candidates in development, possible correlates of protection and current status of immunogenicity assays. Future potential vaccine development pathways to licensure and use in LMICs, trial design and implementation options are discussed, with the objective to provide a basis for reflection, rather than recommendations.

Item Type: Article
Additional Information: © 2016 Kobayashi M. et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Group B Streptococcus, low- and middle-income countries, maternal vaccination, neonatal sepsis, phase III trial, vaccine development
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: F1000Res
ISSN: 2046-1402
Language: eng
Dates:
DateEvent
22 September 2016Published
8 September 2016Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
001World Health OrganizationUNSPECIFIED
OPP1134011Bill and Melinda Gates Foundationhttp://dx.doi.org/10.13039/100000865
PubMed ID: 27803803
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/110776
Publisher's version: https://doi.org/10.12688/f1000research.9363.1

Actions (login required)

Edit Item Edit Item